By targeting proteins used to splice genes, UC San Diego researchers have unlocked a new approach to treating triple-negative breast cancer, the most aggressive and difficult to treat subtype of the disease.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
